slides · global inventory
Diagram
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 23,622
Current window 15,841-15,870
Pages 788
Rows per page 30
Component
15,841-15,870 of 23,622
60
The slide uses a simple input-process-output flow to demystify LLM inference.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
65
The chart uses a logarithmic scale to demonstrate the divergence between sequential CPU performance and accelerated computing/AI performance.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
68
The slide uses a process flow diagram to explain the technical workflow of the company's core technology.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
70
Includes a diagram illustrating the progression from specific task models to general foundation models.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
71
The slide uses a process flow diagram to map specific AI models to stages of drug discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
78
The slide uses a process flow framework to show the integration of AI across the drug development lifecycle.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
79
The slide outlines a proprietary workflow combining AI-driven design with experimental validation.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
84
The slide uses a process flow framework to show the progression from target discovery to optimized antibodies.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
90
The slide uses a process diagram to show the AI workflow and a table to quantify the binding affinity (nM KD) improvements.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
101
The slide illustrates a dual-pathway process leading to a unified AI-driven optimization step.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
103
The slide outlines a proprietary R&D workflow for antibody discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
22
The funnel diagram illustrates the selection criteria: Monomer/Trimer binder -> Picomolar potency -> Extended half-life.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
28
The slide uses a biological process diagram to illustrate the mechanism of action for three distinct therapeutic assets.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
22
The slide uses a funnel diagram to illustrate the selection process from initial discovery sets to final candidate properties.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
25
The slide uses a timeline to frame recent industry activity as validation for the company's asset.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
29
The slide uses a biological process diagram to map drug targets to specific cellular mechanisms (T-cell trafficking, Colonic Fibrosis, Inflammatory cascade, Th17 maturation).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
16
The timeline uses a diagonal layout with numbered steps.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Satisfaction1 hit
12
Uses a vertical process flow diagram to represent development stage gates.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
16
The slide uses a process flow diagram to illustrate the progression of the clinical trial cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
20
The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
22
The slide outlines a clinical trial protocol with three distinct cohorts and specific dosing schedules.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
23
Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram for the mechanistic combinations.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
27
The slide uses a process diagram to show the IL-18 signaling cascade (IL-18 -> MYD88 -> IRAK -> NFkB -> IFNy) and a numbered list to detail its immunomodulatory functions.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
28
Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
32
The slide uses a process flow diagram to explain the therapeutic mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
15
The slide illustrates the escalation of doses for both SAD and MAD study arms.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
18
The diagram illustrates a 4-way cross-over design with 4 patients, each receiving a different sequence of placebo and three dose levels (1mg, 3mg, 8mg).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.Arbutus Biopharma | Investor Presentation Deck | 25 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a process-oriented flow diagram to explain the mechanism of action for a combination therapy.Arbutus Biopharma | Investor Presentation Deck | 25 slides · Arbutus Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit